Rheumatoid arthritis patients on anti-TNFα treatment
| Patient ID | Age | Sex | Disease duration (years) | Anti-TNF drug | MTX | Pred | RhF | Anti-CCP | Pre-treatment DAS | Post-treatment DAS |
|---|---|---|---|---|---|---|---|---|---|---|
| TNFRA02 | 40 | F | 2 | Adalimumab | + | − | + | + | 5.27 | 2.77 |
| TNFRA04 | 57 | M | 4 | Etanercept | + | − | + | + | 7.17 | 2.12 |
| TNFRA05 | 76 | F | 1 | Etanercept | + | + | + | + | 7.46 | 4.43 |
| TNFRA07 | 49 | F | 25 | Etanercept | + | − | − | ND | 7.42 | 6.77 |
| TNFRA08 | 40 | F | 4 | Etanercept | + | − | − | − | 7.08 | 6.34 |
Anti-CCP, anti-cyclic citrullinated peptide antibodies; DAS, disease activity score; F, female; ID, identification; M, male; MTX, methotrexate therapy; ND, not determined; Pred, prednisone therapy; RhF, rheumatoid factor; TNFα, tumour necrosis factor alpha; TNFR, tumour necrosis factor receptor.